Cargando…

Advanced Care Provider and Nursing Approach to Assessment and Management of Immunotherapy-Related Dermatologic Adverse Events

Advanced care providers (ACPs) and nurses are fundamental players in the assessment and management of immunotherapy-related dermatologic adverse events (irdAE). Pembrolizumab, nivolumab, and ipilimumab are approved for unresectable or metastatic melanoma, metastatic non–small cell lung cancer (pembr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ciccolini, Kathryn, Lucas, Anna Skripnik, Weinstein, Alyona, Lacouture, Mario
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Harborside Press 2017
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995492/ https://www.ncbi.nlm.nih.gov/pubmed/29900022

Ejemplares similares

Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma
por: Lacouture, Mario E., et al.
Publicado: (2020)

Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines
por: Lacouture, Mario E., et al.
Publicado: (2020)

Management of Dermatologic Toxicities Associated With Targeted Therapy
por: Lacouture, Mario E.
Publicado: (2016)

“Skin rashes” and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management
por: Sollena, Pietro, et al.
Publicado: (2021)

Dermatologic events from EGFR inhibitors: the issue of the missing patient voice
por: Tischer, Bernd, et al.
Publicado: (2016)

Expert guidance on prophylaxis and treatment of dermatologic adverse events with Tumor Treating Fields (TTFields) therapy in the thoracic region
por: Anadkat, Milan J., et al.
Publicado: (2023)

Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin
por: Lacouture, Mario E, et al.
Publicado: (2022)

Understanding and Managing Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Advanced Melanoma
por: Weinstein, Alyona, et al.
Publicado: (2017)

Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer
por: Rahman, Md. Mominur, et al.
Publicado: (2022)

Management of immune checkpoint inhibitor‐related dermatologic adverse events
por: Si, Xiaoyan, et al.
Publicado: (2019)

Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy
por: Olsen, T. Anders, et al.
Publicado: (2022)

Adverse Events of Oncologic Immunotherapy and Their Management
por: Barber, Fedricker Diane
Publicado: (2019)

Dermatologic immune-related adverse events: The toxicity spectrum and recommendations for management
por: Apalla, Zoe, et al.
Publicado: (2021)

Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel()()
por: Cury-Martins, Jade, et al.
Publicado: (2020)

Gastrointestinal adverse events of immunotherapy
por: Cappello, Giovanni, et al.
Publicado: (2021)

Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management
por: Musiek, Amy C. M., et al.
Publicado: (2021)

The association between adverse events and outcome under checkpoint inhibitors: Where is the deal?
por: Milano, Gerard, et al.
Publicado: (2020)

Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma
por: Lacouture, Mario E., et al.
Publicado: (2016)

Management of immune-related cutaneous adverse events with dupilumab
por: Kuo, Alyce Mei-Shiuan, et al.
Publicado: (2023)

DERMATOLOGY FOR NURSES
Publicado: (1947)

Neurologic adverse events of cancer immunotherapy
por: de Brito, Marcelo Houat
Publicado: (2022)

Supporting Virtual Dermatology Consultation in the Setting of COVID-19
por: Kutner, Allison, et al.
Publicado: (2021)

Patient voice on management of facial dermatological adverse events with targeted therapies: a qualitative study
por: Yagasaki, Kaori, et al.
Publicado: (2019)

NQPC-9 CHARACTERIZATION AND MANAGEMENT OF DERMATOLOGIC ADVERSE EVENTS WITH OPTUNE® IN WAKAYAMA MEDICAL UNIVERSITY HOSPITAL
por: Fukai, Junya, et al.
Publicado: (2022)

High Grade Dermatologic Adverse Events Associated With Immune Checkpoint Blockade for Cancer
por: Kuo, Alyce M., et al.
Publicado: (2022)

A Review of Bullous Dermatologic Adverse Events Associated with Anti-Cancer Therapy
por: Parisi, Rose, et al.
Publicado: (2023)

Occupational Stressors in Nurses and Nursing Adverse Events
por: Karimi, Azam, et al.
Publicado: (2018)

Xerosis and pruritus as major EGFRI-associated adverse events
por: Clabbers, Julia M. K., et al.
Publicado: (2015)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
por: Brahmer, Julie R, et al.
Publicado: (2021)

Balancing the Risk of Adverse Events against the Efficacy of Immunotherapy in Advanced Thymic Epithelial Tumors
por: Ohm, Birte, et al.
Publicado: (2022)

Rheumatological Adverse Events Following Immunotherapy for Cancer
por: Cretu, Ioana, et al.
Publicado: (2022)

Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
por: Lacouture, Mario, et al.
Publicado: (2018)

Immune-related adverse events during anticancer immunotherapy: Pathogenesis and management
por: Stucci, Stefania, et al.
Publicado: (2017)

Providing dermatologic care in Botswana
por: Chang, Aileen Yenting, et al.
Publicado: (2010)

Nintedanib in advanced NSCLC: management of adverse events
por: Lemmens, Liesbeth
Publicado: (2016)

Understanding adverse events of immunotherapy: A mechanistic perspective
por: Burke, Kelly P., et al.
Publicado: (2020)

Immune-related adverse events and the balancing act of immunotherapy
por: Conroy, Michael, et al.
Publicado: (2022)

IL12/23 Blockade with Ustekinumab as a Treatment for Immune-Related Cutaneous Adverse Events
por: Gu, Stephanie L., et al.
Publicado: (2023)

Retrospective analysis of dermatologic adverse events associated with hydroxychloroquine reported to the US Food and Drug Administration
por: Lipner, Shari R., et al.
Publicado: (2020)

Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma
por: Corominas, Josep, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_j3i1ueah6n88j3vqim8mt4np69